1.Specimen handling and tissue preaparation in pre-analytical phase of HER2 testing at tertiary referral hospitals of Metro Manila.
Imperial Marlowe S. ; Tanael Susano B. ; Avila Jose Ma C. ; Tiambeng Ma. Lourdes A.
Acta Medica Philippina 2015;49(2):48-53
INTRODUCTION: HER2 test result depends on a good quality histological section of the breast specimen. Laboratories that process specimens using sophisticated and molecular testing should receive suitable specimen for more accurate results and less waste of expensive resources.
METHODS: A questionnaire based on the ASCO-CAP Guidelines for HER2 testing was developed and administered to pathologists from the local laboratories of Metro Manila-Philippines tertiary referral hospitals. Questionnaire responses were analyzed using descriptive statistics.
RESULTS: Most laboratories did quality control/quality assessment monitoring for the pre-analytic, analytic,post-analytic and turn¬around time phases. Many transported their specimens from the operating room to the laboratory
CONCLUSION: Even in standardized procedures, small variations in sample processing for IHC and FISH can still occur. Inexperienced laboratories will have greater problems interpreting HER2 status results. Laboratories should look into their system in handling specimens for an accurate HER2 testing towards quality assurance.
Human ; Male ; Female ; Breast ; Surveys And Questionnaires ; Pathologists ; Laboratories ; Quality Control
2.Multidisciplinary team management of a patient with placenta percreta for elective cesarean section.
Acta Medica Philippina 2014;48(4):59-63
The incidence of placenta previa/percreta are increasing in numbers and accounts for high maternal morbidity and mortality. This is a case of placenta previa/percreta successfully managed by multidisciplinary team. This case demonstrates that adequate knowledge, effective communication, and the availability and utilization of resources all play significant roles. The team includes an obstetrician, gynecologic oncologist, urologist, vascular surgeon, anesthesiologist, neonatologist, and blood bank and nursing personnel. Prenatal identification of risk factors and diagnosis aid in the implementation of treatment strategies by team. Team effort and elective delivery in a tertiary hospital is essential to improve both maternal and neonatal outcome.
Human ; Female ; Adult ; Placenta Previa ; Blood Banks ; Placenta Accreta ; Delivery, Obstetric ; Elective Surgical Procedures ; Patient Care Team
3.Understanding current attitudes in HER2 testing for breast cancer at tertiary referral hospitals of Metro Manila, Philippines.
Orolfo-Real Irisyl ; Tanael Susano B. ; Avila Jose Ma C. ; Ngelangel Corazon A. ; Tiambeng Ma. Lourdes A.
Acta Medica Philippina 2015;49(2):42-47
INTRODUCTION: The difficulty of obtaining accurate and reproducible assessment of HER2 status in the Philippines, despite the predictive value of the test for HER2 positive breast cancer patients, may be sufficiently addressed if an effective multidisciplinary approach to HER2 testing is carried out. This may be accomplished by identifying disparities and similarities in HER2 testing for breast cancer.
METHODS: This is a cross-sectional study which included medical oncologists who had used trastuzumab for HER2-positive patients. Surgeons, who belonged to the same tertiary hospital as the medical oncologists were also interviewed. The survey questionnaires were administered via face-to-face, mail, or fax. Responses were kept confidential. Questionnaire responses were analysed using summary statistics.
RESULTS: There were 35 medical oncologists and 37 surgeons - 93% stated that all women diagnosed with breast cancer should be tested for HER2 at the point of diagnosis; 61% stated that the greatest barrier to initiating HER2 testing was inadequate patient funds. 57% medical oncologists and 65% surgeons believed that HER2 testing for all breast cancer patients at the point of clinical diagnosis was being observed at their hospital. 69% stated that medical oncologists or surgeons should request for HER2 test whoever saw the patients first; 59% stated that whoever saw the patient first provide the patient information about HER2 testing whereas 28% stated it is the medical oncologist who should provide information about HER2 testing. 47% medical oncologist and 63% surgeons stated that surgeons should arrange for breast tissue sample collection; 27% medical oncologists and 20% surgeons stated that pathologists should do this.
CONCLUSION: Medical oncologists and surgeons were similar in the opinion that all women diagnosed with breast cancer should be tested for HER2 at the point of diagnosis, financial capability was the greatest barrier for initiating HER2 testing, and whoever saw the patient first should provide patient education. There was disparity on who should request and who should arrange for tissue collection.
Human ; Male ; Female ; Aged ; Middle Aged ; Adult ; Philippines ; Breast Neoplasms ; Oncologists ; Surgeons ; Surveys And Questionnaires
4.Bedside transthoracic 2D echo-guided blade atrial septostomy: First reported case in the Philippines.
Cheng Dexter Eugene D ; Magadaeg-Capero Maycibel D
Acta Medica Philippina 2014;48(4):64-67
A nonrestrictive interatrial communication is mandatory in some patients with complex cyanotic heart disease. Up to the present time, Park blade atrial septostomy with a Park blade catheter is performed only under fluoroscopic guidance. We successfully monitored only under transthoracic 2-dimensional (2D) echocardiography (TTE), in a 7-week-old infant with d-Transposition of Great Arteries (d-TGA), a restrictive patent foramen ovale (PFO), and small ventricular septal defect (VSD), who presented with severe hypoxemia. TTE confirmed the position of the blade before and during pullback to the right atrium, followed by balloon septoplasty. There was an adequate enlargement of the interatrial communication with subsequent improvement in the oxygenation of the infant. This is the first reported case of the performance of blade atrial septostomy as a bedside TTE guided procedure here in the Philippines.
Human ; Male ; Infant ; Heart Septal Defects, Ventricular ; Foramen Ovale, Patent ; Philippines ; Echocardiography ; Heart Atria ; Cardiac Surgical Procedures ; Transposition Of Great Vessels ; Hypoxia
5.A case of a 42-year-old Filipino male with bilateral lower extremity swelling.
Timbol Edgar Wilson G ; Racaza Geraldine Z ; De Las Alas Jacqueline Michelle G ; Duya Jose Eduardo DL ; Mejia Agnes D
Acta Medica Philippina 2014;48(4):68-74
A 42-year-old male was admitted at the University of the Philippines-Philippine General Hospital (UP-PGH) for a 3-month history of non-healing wound in the medial side of his right leg in spite of multiple antibiotics. The wound worsened with multiple ulcerations and draining sinuses. The wound was shown to have suppurative and granulomatous infiltrates that yielded Mycrobacterium tuberculosis. An algorithm in the approach to a chronic or non-healing wound is discussed.
Human ; Male ; Adult ; Hospitals, General ; Anti-bacterial Agents ; Suppuration ; Tuberculosis ; Communicable Diseases ; Lower Extremity
6.A case of a 39-year-old immunocompromised Filipino male with non-healing wound of the right lower leg.
Lao Janice Jill K ; Tan Tennille S ; Bello Alex P ; Uichangco-Bravo Malen ; Ruiz-Jacinto Emily ; Corpuz Allan D ; Mejia Agnes D
Acta Medica Philippina 2014;48(4):75-79
This a case of a 39-year-old Filipino male with systemic lupus erythematosus (SLE) diagnosed in 2006, presenting with a 3-month history of non-healing wound on his right lower leg. This paper will discuss the etiologies of a non-healing wound and present an algorithm to guide the approach to diagnosis and management.
Human ; Male ; Adult ; Lupus Erythematosus, Systemic ; Algorithms
7.The effect of DOH-PCSI patient navigation access program for breast cancer on quality of care at the Medical Oncology Clinic at the Philippine General Hospital: The 1st 6 months.
Patdu Ma. Pamela D. ; Liangco Wilfredo L. ; Ngelangel Corazon A. ; Guerrero Anna Melissa S. ; Ala Ma. Victoria G. ; Rosario Rachel Marie B. ; Marcaida Romeo V.
Acta Medica Philippina 2015;49(2):5-12
INTRODUCTION: Cost has become a limiting factor for indigent breast cancer patients at the Philippine General Hospital (PGH). The Department of Health-Philippine Cancer Society Inc (DOH¬PCSI) Access Program for Breast Cancer Medicine provided free chemotherapy through a patient navigation system in PGH starting January 2012 to improve breast cancer treatment quality. This study looked into the differences of quality care in the non-metastatic setting among enrolled patients in the first 6 months compared to patients outside of the program from 2011-2012.
METHODS: This retrospective cohort used follow-up rates and 19 quality care indicators linked to improved outcomes to look into quality of care among patients who were enrolled (n=58) and those who were not (n=118 for 2011 and 2012). Subgroup analyses compared patients in the program and those who were not included in the same period (n=28). Another analysis compared 2011 patients (n= 90) with those in 2012 (n=86). Z¬test for the difference of proportions was done.
RESULTS: Attrition rate decreased from 62% in 2011 to 18% in 2012 (p<.0001). There was a significant improvement in 12 quality care indicators in the program (95% Cl), with the greatest differences in the initiation of treatment (58.7%) and appropriate neo-adjuvant chemotherapy administration (58.3%). Similar trends were seen in the subgroup analyses.
Conclusion. The DOH-PCSI Access Program for Breast Cancer Medicine program improved care among breast cancer patients in PGH, noted as early as within its first six months.
Human ; Male ; Female ; Breast Neoplasms ; Patients ; Drug Therapy ; Breast ; Philippines
8.Impact of histopathological profile on disease progression of breast cancer patients during the 1st 1-2 years follow-up: Evidence from the Philippine DOH-Breast Cancer Medicine Access Program.
Semira Marie Christine G. ; Balbuena Joanne Marie L. ; Htur-Javier Vanina ; Sandoval-Tan Jennifer ; Ngelangel Corazon A. ; Guerrero Anna Melissa S ; Rosario Rachel Marie B. ; Mercaida Romeo V.
Acta Medica Philippina 2015;49(2):13-17
INTRODUCTION: Current international consensus confirms that certain histopathologic factors such as tumor morphology, histologic grade and presence of lymphovascular invasion are correlated with prognosis. This retrospective cohort study evaluated the correlation between histopathologic profile and time to disease progression (UP) within the first 1-2 years follow-up of Filipino Stage I-Ill early breast cancer patients.
METHODS: This is a retrospective cohort study which included breast cancer patients enrolled in the Department of Health¬Breast Cancer Medicine Access Program (DOH-BCMAP) at the medical oncology clinics of two tertiary hospitals in Manila. Clinical and histopathologic factors were gathered from patient records, and the patients were grouped according to the modified St. Gallen definition of risk categories for patients with breast cancer. Kaplan-Meier survival analysis determined the average UP as well as progression-free survival (PFS). Multivariate logistic regression determined factors contributing to disease progression.
RESULTS AND CONCLUSION: Of the 326 patients enrolled in this study, 18% showed progression, with a median HP of 14 months. UP was comparable among the low-, intermediate- and high-risk groups. PFS during the 1st 1-2 years follow-up was estimated to be at 78% for the high-risk group, 83% for the intermediate-risk group, and 86% for the low-risk group. During this 1st 1-2 years follow-up, no studied factors of interest were shown to be significantly correlated with outcome among this predominantly intermediate to high risk for recurrence breast cancer patients. Follow-up of this patients up to 5 or more years would define sustained gains from the DOH-BCMAP.
Human ; Male ; Female ; Breast ; Breast Neoplasms ; Consensus ; Neoplasms ; Prognosis ; Medical Oncology
9.Immunohistochemical profile, pattern of recurrence, and time to progression of non-metastatic breast cancer patients of the Department of Health-Breast Cancer Medicines Access Program.
Laja Nelson A. ; Lui Arthur Gregory A. ; Gumapon Joar Kent P. ; Ngelangel Corazon A. ; Guerrero Anna Melissa S. ; Sacdalan Dennis L. ; Rosario Rachel Marie B. ; Marcaida Romeo V.
Acta Medica Philippina 2015;49(2):18-25
BACKGROUND: Breast cancer remains to be the leading cause of malignancy among women and survival rates vary worldwide. Molecular and immunohistochemical (NC) profiling of breast cancer has emerged to improve treatment, which led to 6 different breast cancer subtypes luminal-A, luminal-B, Her-2 enriched, basal-like, daudin low, and normal breast. Essentially, this guides clinicians as to the choice of treatment and prognostication of disease. This study evaluates the characteristics of the different IHC subtypes of breast cancer among Filipinos as to pattern of recurrence and time to progression (TIP) within their 1st 2 years of follow-up.
METHODS: This is a retrospective cohort study, approved by the University of the Philippines Manila Research Ethics Board (UPMREB). Study population included breast cancer patients enrolled in the DOH-BCMAP and managed at the medical oncology clinics of the Philippine General Hospital (PGH) and Jose R. Reyes Memorial Medical Center (JRRMMC) from 1 May 2011 to 31 December 2013. Patients' demographics, disease and treatment profile were gathered from the medical charts. Patients were grouped into 12 different IHC subtypes utilizing only IHC staining results of Her2neu, ER and PR. Disease progression/ relapse and time to progression (UP) were primary outcomes analyzed and compared between subtypes using SPSS.
RESULTS: There were 368 eligible patients; 50% were >50 years old, 48% postmenopausal, 34% stage IIA, and 94% had invasive ductal carcinoma. About 88% completed their chemotherapy regimen, mostly AC-T. At 1 to 2 years follow-up, 18% had disease progression, mostly distant metastasis, with HER2neu(-)/ER(-)/PR(-), HER2(+), and HER2neu(-)/ER(+)/PR(+) subtypes having the most number of disease progression. The HER2neu(-)/ER(-)/PR(-) subtype had the shortest median TTP (11 months 9sd). HER2(+) subtype had median TTP of 14±8 sd, while HER2neu(-)/ER(+)/PR(+) had median TTP at 11.6±7.41 sd. The median TTPs among the different IHC subtypes were statistically comparable.
CONCLUSION: Filipinas with non-metastatic breast cancer after surgery and mainly on adjuvant chemotherapy started to develop disease progression/ relapse within the first 2 years of follow-up; 82% had no relapse. At these early years of follow-up, the median TTPs among the different breast cancer IHC subtypes who went into relapse were comparable, although HER2neu(+) regardless of ER/PR subtype tended to have more disease progression, followed by HER2neu(-)/ ER(-)/ regardless of PR subtype, and then HER2neu(-)/ ER(+)/ regardless of PR subtype. IHC resultant HER2neu(+) regardless of ER/PR and HER2neu(-)/ER(-)/PR(-/+) subtypes can serve as early prognosticators of breast cancer relapse.
Human ; Male ; Female ; Aged 80 And Over ; Aged ; Middle Aged ; Adult ; Breast Neoplasms ; Neoplasms ; Survival Rate ; Carcinoma ; Drug Therapy ; Medical Oncology
10.Chemotherapy-induced neutropenia, anemia and thrombocytopenia among Filipino breast cancer patients on adjuvant hemotherapy.
Tia Lou Jorel P. ; Lui Arthur Gregory A. ; Chua Noel S. ; Strebel Heinrik Martin Jude S.
Acta Medica Philippina 2015;49(2):26-31
INTRODUCTION: Cytotoxic chemotherapy places all cancer patients at risk of developing myelosuppression. Different chemotherapy regimens could lead to development of neutropenia, anemia and thrombocytopenia which may lead to delays in facilitating chemotherapy and also may place cancer patients at risk of developing severe complications which may be life threatening. This study determined the incidence of neutropenia, anemia, and thrombocytopenia per cycle of chemotherapy starting after the 1st cycle among non-metastatic breast cancer patients. It also evaluated if age, size of primary tumor, number of positive lymph nodes, IHC result, BMI, co-morbidities and chemotherapy used were associated with the development of neutropenia, anemia and thrombocytopenia during the 10 cycle of chemotherapy; this may help in ascertaining which patients may need more intensive monitoring during subsequent chemotherapy sessions.
METHODS: This is a time series study wherein the CBC results starting prior 1° chemotherapy cycle were gathered from medical charts of non-metastatic breast cancer patients receiving cyclophosphamide/ doxorubicin/ docetaxel/ fluororuracil chemotherapy at UP-PGH and JRRMMC Medical Oncology Clinics enrolled under the DOH-NCPAM BCMAP program, from 1 January 2009 to 31 June 2014. Incidence rates of neutropenia, anemia and thrombocytopenia were recorded per cycle of chemotherapy. Severity of myelosuppression was graded based on the Common Toxicity Criteria of the National Cancer Institute Version 2.0. Possible predictors of myelosuppression were assessed focusing on the 1st cycle of chemotherapy where interventions were not yet done. Standard statistical methods were used for the descriptive analysis. Variables were analyzed using the Chi square test and logistic regression; level of significance was at p<0.05.RESULTS: 751 patients were included in the study, who had a total of 3,759 CBC results. The incidence of neutropenia, anemia, thrombocytopenia for all 3,759 CBC results were 3%, 2.3%, and 0.5%, respectively. Among all recorded CBC results only 0.9% had grade 3-4 neutropenia and 0.3% grade 3-4 anemia. There was no severe thrombocytopenia.
After the 1st chemotherapy cycle, the incidence of neutropenia was 4.67% (35 patients), anemia 2.27% (17 patients), and thrombocytopenia 0.8% (6 patients). Of these patients, only 1.17% (9 patients) experienced severe neutropenia and 0.27% (2 patients) experienced grade 3-4 anemia. No patient experienced grade 3-4 thrombocytopenia.
Age, size of primary tumor, number of positive lymph nodes, IHC result, BMI, co-morbidities and chemotherapy used were not associated with risk for myelosuppression during the 1st cycle of chemotherappy.
CONCLUSION: Incidence rates of neutropenia, anemia and thrombocytopenia were minimal in non-metastatic breast cancer patients undergoing cytotoxic chemotherapy, with low rates of severe myelosupression. Myelosupression from standard doxorubicin/ cyclophosphamide/ docetaxel/ fluoracil containing chemotherapy regimens can be given to non-metastatic breast cancer patients, completing required number of chemotherapy cycles with nil interruption or delay.
Human ; Male ; Female ; Breast ; Breast Neoplasms ; Neutropenia ; Anemia ; Thrombocytopenia ; Incidence ; Cyclophosphamide ; Drug Therapy